Connect with us

Technology

YouScript Wins “PharmaTech Innovation Award” in 9th Annual MedTech Breakthrough Awards Program

Published

on

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies

SEATTLE, May 8, 2025 /PRNewswire/ — YouScript®, an Aranscia company, today announced that it is the recipient of the “PharmaTech Innovation Award” award in the 9th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market.

The 2025 MedTech Breakthrough Award recognizes the industry-leading innovations of the YouScript Precision Prescribing platform and its positive impact on millions of patients’ lives. As one of the foundational leaders in personalized medication management for over two decades, YouScript’s award-winning solutions, extensive program experience, and tested and proven operations teams provide distinct advantages in the design, execution, and success of personalized prescribing programs. Studies show that that YouScript-powered programs have helped to reduce hospitalizations and emergency department visits by 39% and 71%, respectively.

The power of YouScript’s technology platform lies within intuitive capabilities that assist providers to make intelligent, proactive medication decisions at the point of care. YouScript provides evidence-based guidance on drug and dose selection incorporating pharmacogenomics (PGx), drug-drug interactions, and phenoconversion, plus a patented framework for proactive risk assessments to highlight the direct potential impact of personalized prescribing. YouScript’s decision support technologies, which contain drug-gene insights from over 19,000 high-evidence references covering over 2,000 medications, are widely available via EMR integrations, standalone applications, and APIs.

“YouScript’s suite of technology and program solutions highlight a foundational mission to help unlock the true power of precision prescribing for all,” said Kristine Ashcraft, Founder and President of YouScript. “We are proud of our continued growth and expansion as a trusted partner to value-based healthcare organizations, providers, and payers, and we thank MedTech Breakthrough for this incredible recognition.”

The MedTech Breakthrough Awards program celebrates excellence and innovation in the health and medical technology industry, recognizing the companies, products, and solutions driving meaningful progress and improving patient care. Spanning a wide range of categories—including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data & Privacy, and beyond—the awards highlight the groundbreaking work that is transforming the healthcare landscape.

This year’s program saw a record-breaking number of nominations from leading companies and startups across more than 18 countries, showcasing the global impact and momentum of the digital healthcare industry today.

“YouScript is an industry-leading provider of medication management solutions that unlock the true power of precision prescribing for all,” said Steve Johansson, managing director, MedTech Breakthrough. “YouScript identifies substantially more major issues than typical drug-drug interaction programs, allowing healthcare providers to reduce trial-and-error prescribing, reduce costs, and improve patient outcomes. We’re thrilled to award YouScript with the ‘PharmaTech Innovation Award!'”

YouScript technology is also now powering alerting-based precision medicine solutions for thousands of individual client groups, pharmacy systems, long-term care systems, and pharmacy benefit managers that collectively support millions of patient lives.

About YouScript
YouScript is a leader in pharmacogenomics research, insights, and software solutions that help make precision prescribing possible. YouScript’s lab-agnostic PGx risk, insights, and reference solutions assist clinical professionals to make fast, proactive decisions at the point of care. YouScript’s PGx program support and research initiatives span more than two decades and have often served as a foundational basis for best practices in assessing categorial risk and measuring outcomes across the entire PGx industry. For more information, please visit www.youscript.com.

About Aranscia
Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia’s portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more information, please visit www.aranscia.com

About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

Media Contact:
Karina Stabile
394951@email4pr.com
(516) 317-5835

View original content to download multimedia:https://www.prnewswire.com/news-releases/youscript-wins-pharmatech-innovation-award-in-9th-annual-medtech-breakthrough-awards-program-302450330.html

SOURCE YouScript

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Waystar Announces Pricing of Public Offering of Common Stock

Published

on

By

LEHI, Utah and LOUISVILLE, Ky., May 14, 2025 /PRNewswire/ — Waystar Holding Corp. (Nasdaq: WAY) (“Waystar”), a provider of leading healthcare payments software, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock by certain investment funds of EQT AB and Bain Capital, LP, and Canada Pension Plan Investment Board (CPP Investments), and their respective affiliates (collectively, the “Selling Stockholders”) at a price to the public of $38.75 per share.  Additionally, the Selling Stockholders have granted the underwriters a 30-day option to purchase up to 1,875,000 additional shares of common stock. Waystar is not selling any shares and will not receive any proceeds from the sale of shares in the offering by the Selling Stockholders. The offering is expected to close on or about May 16, 2025, subject to customary closing conditions.

The offering is being made through an underwriting group led by J.P. Morgan, Goldman Sachs & Co. LLC, and Barclays, who are acting as joint lead book-running managers and as representatives of the underwriters for the offering. William Blair, Evercore ISI, BofA Securities, RBC Capital Markets, Jefferies and Deutsche Bank Securities are acting as joint bookrunners for the offering. Canaccord Genuity and Raymond James are acting as co-managers for the offering.

A registration statement on Form S-1, including a prospectus, relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

The offering may be made only by means of a prospectus. Copies of the preliminary prospectus may be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts. The words “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” the negative version of these words, or similar terms and phrases are intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations and are inherently subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the offering and other risks described in Waystar’s registration statement on Form S-1, as it may be amended from time to time, and its Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent filings with the SEC. Except as required by law, Waystar has no obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

About Waystar

Waystar’s mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar’s enterprise-grade platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities.

Media Contact
Kristin Lee
kristin.lee@waystar.com

Investor Contact
Sandy Draper
investors@waystar.com 
502-238-9511

View original content to download multimedia:https://www.prnewswire.com/news-releases/waystar-announces-pricing-of-public-offering-of-common-stock-302455962.html

SOURCE Waystar

Continue Reading

Technology

PIF’s Joint Venture with Hyundai Motor Company, Hyundai Motor Manufacturing Middle East, celebrates groundbreaking milestone

Published

on

By

Paving the way for a new industrial futureThe new facility is a joint venture between PIF and Hyundai Motor CompanyThe plant will manufacture internal combustion engine and electric vehicles, with an annual production target of 50,000 vehicles to supply Saudi Arabia

KING ABDULLAH ECONOMIC CITY, Saudi Arabia, May 15, 2025 /PRNewswire/ — Hyundai Motor Manufacturing Middle East (HMMME), a joint venture between PIF and Hyundai Motor Company, today hosted its groundbreaking ceremony in the recently announced King Salman Automotive Cluster within King Abdullah Economic City (KAEC). The ceremony is a significant milestone that marks another step in the development of the automotive industry in the Kingdom of Saudi Arabia.

PIF owns a 70% stake in HMMME, with Hyundai holding the remaining 30%. The manufacturing plant, Hyundai’s first facility in the Middle East, will roll out its first vehicle by the fourth quarter of 2026 and targets an annual production of 50,000 vehicles. This will include both internal combustion engine (ICE) and electric vehicles (EV).

Yazeed A. Alhumied, Deputy Governor and Head of MENA Investments at PIF, said: “This groundbreaking is a significant milestone for PIF as it further strengthens the automotive industry in Saudi Arabia. PIF will continue to enable and accelerate the growth of Saudi Arabia’s automotive ecosystem through partnerships. This joint venture underscores PIF’s commitment to build local capabilities, attract cutting-edge technology, and create highly skilled jobs in Saudi Arabia’s automotive and mobility sector.”

Jaehoon Chang, Hyundai Motor Group Vice Chair said, “Today’s groundbreaking marks the beginning of a new chapter for both the Kingdom of Saudi Arabia and Hyundai Motor Company, as we lay the foundation for a new era of future mobility and technological innovation. Through our joint venture, we hope to contribute to the development of talent in the region with advanced skills and capabilities under Saudi Vision 2030.”

Wongyun Park, Vice President and CEO of Hyundai Motor Manufacturing Middle East said, “With HMMME, we are driving change forward and paving the way for a new industrial future in the region. The facility will become a platform for growth and industrial excellence in the heart of the Kingdom.”

HMMME is building a foundation for a new era of automotive manufacturing in Saudi Arabia. Harnessing the skills of the local workforce, the new manufacturing plant will create thousands of jobs and allow for knowledge transfer and skills development. The localization of Hyundai’s vehicles will accelerate the growth of Saudi Arabia’s automotive and mobility ecosystem and pave the way for a new industrial future.

This partnership is one in a series of PIF initiatives establishing Saudi Arabia as a global automotive player. Together, these initiatives are driving transformation in the sector, and boosting domestic manufacturing capabilities, infrastructure, and supply chains.

Photo – https://mma.prnewswire.com/media/2687900/Image_1___HMMME_Groundbreaking_Ceremony.jpg

Photo – https://mma.prnewswire.com/media/2687901/Image_2___HMMME_Facility_Site__Rendered_Image.jpg

PDF – https://mma.prnewswire.com/media/2687273/PIF_s_Joint_Venture_with_Hyundai_Motor_Company__Hyundai_Motor_Manufacturing_Middle_East__celebrates.pdf

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/pifs-joint-venture-with-hyundai-motor-company-hyundai-motor-manufacturing-middle-east-celebrates-groundbreaking-milestone-302455922.html

Continue Reading

Technology

BREAKING BARRIERS: HOW TIM WHITE IS REDEFINING INTERNATIONAL RACE ENGINEERING FROM NEW ZEALAND

Published

on

By

CROMWELL, New Zealand, May 14, 2025 /PRNewswire/ — In a sport where split-second decisions define success, Tim White is proving that world-class race engineering knows no borders. Operating from a small New Zealand town, White has established himself as a leading figure in Ferrari’s GT programs, leveraging cutting-edge remote engineering techniques to optimize performance in global endurance racing.

Founder of Elite Race Engineering, White serves as a Performance and Simulation Engineer, where he develops advanced modeling techniques and refines real-time data processing to enhance on-track performance. His use of innovative sensors, aerodynamic tuning, and sophisticated simulation tools has strengthened the team’s technical capabilities, making him a key player in Ferrari’s GT3 programs. Working remotely with Orlando-based Ferrari racing team Triarsi Competizione, White integrates advanced modeling, sensor technology, and data-driven insights to refine the Ferrari 296 GT3. Despite being based in New Zealand, his ability to analyze massive amounts of real-time race data and communicate findings instantly has made him an invaluable asset to teams in IMSA WeatherTech SportsCar Championship and GT World Challenge Asia.

“Motorsport has always been seen as a hands-on, in-person industry, but technology is changing that,” says White. “From New Zealand, I can help optimize race cars competing on the other side of the world in real-time. Distance isn’t a limitation— it’s just another problem to engineer a solution for.” White’s journey began with an automotive mechanics apprenticeship, where he built and maintained race cars for circuit, rally, and hill climb competitions. A pivotal piece of advice from a Kiwi Formula 1 veteran led him to pursue a mechanical engineering degree, despite having no academic record from school. After years of perseverance, he earned a First-Class Honours degree and secured direct entry into a PhD program before pivoting back to motorsport.

His expertise in vehicle dynamics, simulation, and tire modeling took him around the world—working in IMSA, WEC, BTCC, and V8 Supercars, as well as developing software for race strategy and data management. When the COVID-19 pandemic halted racing, White turned to education, writing and presenting online courses on data analysis and race engineering before launching his own consulting business.

With IMSA’s 2025 torque sensor regulations set to revolutionize its GTD-class racing, White’s expertise in powertrain performance and data analysis ensures that Ferrari remains ahead of the curve. His journey—from building homegrown race cars to shaping the future of GT engineering—proves that innovation isn’t about location, but vision.

View original content:https://www.prnewswire.com/news-releases/breaking-barriers-how-tim-white-is-redefining-international-race-engineering-from-new-zealand-302455965.html

SOURCE Elite Race Engineering

Continue Reading

Trending